


Impact of COVID-19 in Oncology - A Pharma Perspective

Kald Abdallah MD PhD

Senior Vice President - Therapeutic Area Head - Oncology Medical Affairs

Responding to the COVID-19 Crisis: Turning Data into Actions



An Iterative Process: New data is continuously collected and used to recalibrate signals and measure progress of in-flight activities

Signals and Trends Revealed: Representative Learnings



Effects on Clinical Trials

- Recruitment slowed between March and May 2020 as referrals decreased and sponsors enforced measures to protect patients and sites
- As a result, some participants were unable to visit clinical sites, and staff were unable to conduct close-out visits as per protocols
- PI's voiced some degree of frustration at companies' seemingly "aggressive" policies in pausing trials



Other Key Learnings

- **Telemedicine:** COVID accelerated adoption of this new medium of healthcare delivery that protects patients from exposure; particularly useful for routine follow-ups and patients in rural areas
- **Alternative Treatment Delivery:** Providers explored changes to treatment strategy, including preference for oral formulations, home / outsourced care models, and expanded intervals between doses of infusion medicines

Above lists non-exhaustive.

Priorities

1

Protect the safety of patients and personnel at BMS and our clinical trial sites

2

Ensure our scientific integrity and regulatory compliance

3

Ensure continued delivery of our regulatory obligations

Our Actions: From Crisis Recovery to **New Ways of Working**



We leveraged new technologies to protect our patients and sustain our research

- Remote monitoring tactics for clinical trial sites, including access to EMR/EHR
- Patient / investigator virtual visits when data could be collected by telephone or video call
- Further exploring central monitoring capabilities and digital site inspections to minimize non-essential travel to sites and relieve challenges to sponsors and their delegates



We promoted agility and flexibility in our unwavering commitment to patients

- Allowed trial participants to visit alternative clinical centers conducting the same studies or sites providing at least standard-of-care support
- Pilot projects aiming to enable efficiencies through telemedicine and private transport to treatment sites
- Direct-to-patient drug shipments, balancing what is feasible with what is medically appropriate



Recent signals and trends continue to inform us of actions we can take in the areas of clinical trials, as well as COVID-19 vaccines.

Thank you